Assessing the performance of different outcomes for tumor growth studies with animal models
Open Access
- 14 June 2022
- journal article
- research article
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 5 (3) , 248-257
Abstract
The consistency of reporting results for patient‐derived xenograft (PDX) studies is an area of concern. The PDX method commonly starts by implanting a derivative of a human tumor into a mouse, then comparing the tumor growth under different treatment conditions. Currently, a wide array of statistical methods (e.g., t‐test, regression, chi‐squared test) are used to analyze these data, which ultimately depend on the outcome chosen (e.g., tumor volume, relative growth, categorical growth). In this simulation study, we provide empirical evidence for the outcome selection process by comparing the performance of both commonly used outcomes and novel variations of common outcomes used in PDX studies. Data were simulated to mimic tumor growth under multiple scenarios, then each outcome of interest was evaluated for 10 000 iterations. Comparisons between different outcomes were made with respect to average bias, variance, type‐1 error, and power. A total of 18 continuous, categorical, and time‐to‐event outcomes were evaluated, with ultimately 2 outcomes outperforming the others: final tumor volume and change in tumor volume from baseline. Notably, the novel variations of the tumor growth inhibition index (TGII)—a commonly used outcome in PDX studies—was found to perform poorly in several scenarios with inflated type‐1 error rates and a relatively large bias. Finally, all outcomes of interest were applied to a real‐world dataset.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (K01‐HL151754)
This publication has 24 references indexed in Scilit:
- A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor GrowthCancer Research, 2013
- Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer XenograftsMolecular Cancer Therapeutics, 2012
- RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—PointCancer Research, 2012
- Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse modelsJournal of Translational Medicine, 2012
- Patient-derived tumour xenografts as models for oncology drug developmentNature Reviews Clinical Oncology, 2012
- Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic TumorsClinical Cancer Research, 2010
- Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual IssuesPsychiatric Annals, 2008
- BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In VivoCurrent Biology, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Application of random-effects pattern-mixture models for missing data in longitudinal studies.Psychological Methods, 1997